Compare SUN & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUN | PRAX |
|---|---|---|
| Founded | 1886 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.8B | 8.6B |
| IPO Year | N/A | 2020 |
| Metric | SUN | PRAX |
|---|---|---|
| Price | $57.55 | $319.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 15 |
| Target Price | $65.00 | ★ $516.93 |
| AVG Volume (30 Days) | 464.3K | ★ 589.2K |
| Earning Date | 02-17-2026 | 02-27-2026 |
| Dividend Yield | ★ 6.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.93 | N/A |
| Revenue | ★ $21,870,000,000.00 | $7,463,000.00 |
| Revenue This Year | $11.09 | N/A |
| Revenue Next Year | $46.49 | $29,535.93 |
| P/E Ratio | $19.87 | ★ N/A |
| Revenue Growth | N/A | ★ 364.98 |
| 52 Week Low | $47.98 | $26.70 |
| 52 Week High | $59.88 | $326.91 |
| Indicator | SUN | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 58.41 |
| Support Level | $56.80 | $288.57 |
| Resistance Level | $58.49 | $325.22 |
| Average True Range (ATR) | 1.23 | 17.04 |
| MACD | -0.15 | -2.41 |
| Stochastic Oscillator | 31.23 | 67.85 |
Sunoco LP is engaged in the distribution of motor fuels to independent dealers, distributors, and other commercial customers as well as the distribution of motor fuels to end-use customers at retail sites operated by commission agents. It is a growth-oriented master limited partnership (MLP) that operates as a wholesale and retail fuel distributor in the United States. The firm operates through the Fuel Distribution; Pipeline Systems; and Terminals segments. It generates the majority of its revenue from the Fuel Distribution segment. It distributes motor fuel to convenience stores, dealers, and commercial customers in various states. The operating convenience stores are under the APlus, Stripes, Aloha Island Mart, and Tigermarket brands.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.